A Phase 4, Open Label Field Study to Evaluate the Clinical Benefit, Safety, and Pharmacokinetics of Anthim (Obiltoxaximab) When Used in the Treatment of Suspected, Probable, or Confirmed Cases of Inhalational Anthrax Due to B. Anthracis
Latest Information Update: 17 Jul 2023
At a glance
- Drugs Obiltoxaximab (Primary)
- Indications Anthrax
- Focus Therapeutic Use
- Sponsors EluSys Therapeutics
- 12 Jul 2023 Planned End Date changed from 1 Aug 2024 to 1 Dec 2025.
- 12 Jul 2023 Planned primary completion date changed from 1 Aug 2023 to 2 Dec 2023.
- 12 Jul 2023 Planned initiation date changed from 1 Aug 2022 to 1 Dec 2023.